Loading stock data…
KYNB
$7.09-0.18 (-2.48%)
Market ClosedLast close May 1
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kyntra Bio, Inc. in the Healthcare sector is trading at $7.09. The stock is currently 44% below its 52-week high of $12.60, remaining 20.8% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why KYNB maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.09
Potential Upside
5%
Whystock Fair Value$7.44
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$43.00+506.5%
Range$43.00 – $43.00
Fundamentals
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of meta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-610.73%
Volume
Today's trading volume
5,347
Recent News
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ...
Kyntra Bio Inc (KYNB) faces revenue challenges but extends cash runway and advances clinical trials to bolster future growth.
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kyntra Bio, Inc.'s filings with the SEC, including our most recent Form 10-K and Form 10-Q. Kyntra Bio, Inc. does not undertake any obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
Kyntra Bio: Q4 Earnings Snapshot
SAN FRANCISCO (AP) — Kyntra Bio, Inc. KYNB) on Monday reported a loss of $14.2 million in its fourth quarter. The San Francisco-based company said it had a loss of $3.51 per share.
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.